Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • December 2016 •
  • 88 pages •
  • Report ID: 4548607 •
  • Format: PDF
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Summary
Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases.

Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. In 2015, 415 Million people worldwide were estimated to be living with diabetes, a figure that is expected to rise to 642 Million people by 2040 (IDF, 2015). T2DM, which accounts for 85–95% of all diabetes cases, will be the main driver of this growth. This highlights the scale and urgency of the T2DM public health crisis and the need for preventative measures and safe, effective and cost-efficient therapeutics.

According to Chisholm, GBI Research, “In spite of recent developments, there are still significant unmet needs for T2DM. Treatment regimens are often complex, and many drugs have limited long-term efficacy and side effects that are particularly undesirable for the T2DM patient population, such as increased cardiovascular risk factors or weight gain.”

The demand for T2DM therapeutics has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy. The pipeline for T2DM is large, with 591 products in active development, which constitutes approximately one-third of the pipeline for the metabolic disorders therapy area.

T2DM therapeutics can often attract high values in licensing or co-development strategic consolidations. Analysis of licensing and co-development deals relating to T2DM therapeutics since 2006 has identified aggregate deal values of $9.2Billion and $9.5Billion, respectively, for deals with disclosed deal values. However, the majority of first-in-class products in development for T2DM have no disclosed involvement in previous licensing or co-development. Among these products, the range of molecular targets is relatively wide, providing ample and diverse opportunities for potential investors.

The report “Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects” allows you to appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options, iidentifies leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market and recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

Scope
The escalating T2DM public healthcare need has resulted in a competitive market landscape
- What is the pathophysiology of T2DM?
- What are the common co-morbidities and complications?
- How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
- What are the most significant unmet needs within the market?

The T2DM pipeline is large and innovative
- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?

The T2DM deals landscape is highly active
- Do T2DM products attract high deal values?
- Which molecule types and molecular targets dominate the deals landscape?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy
This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the T2DM pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.